NGM Bio Announces Late-Breaking Plenary Presentation At International Liver Conference 2018 Of Detailed Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis

NGM Bio Logo (PRNewsFoto/NGM Biopharmaceuticals, Inc.)PARIS and SOUTH SAN FRANCISCO, Calif., April 13, 2018 /PRNewswire/ — NGM Bio today announced that detailed data from an exploratory Phase 2 study of patients with primary sclerosing cholangitis (PSC) who were treated with NGM282, an engineered analogue of FGF19, will be highlighted in a…

Share this post